Literature DB >> 15221082

[Immune restoration inflammatory syndromes].

M Stoll1, H Heiken, G M N Behrens, R E Schmidt.   

Abstract

Increase of prevalence of certain immunodeficiencies is caused by more frequent use of immunosuppresive treatment, by advances in supportive care of immunodeficient individuals and by the pandemic spread of HIV-infection respectively. Highly active antiretroviral treatment (HAART) is able to reconstitute the impaired immunity in the HIV-infected individual and therefore to reduce morbidity and mortality. On the other hand paradoxical exacerbation of inflammatory or opportunistic diseases may develop during immunoreconstitution. By their distinct pathophysiological, clinical and therapeutic particularities these disease have been summarized as Immune Restoration Inflammatory Syndromes (IRIS). This review summarizes the variety of immunoreconstitution disorders and describes possible diagnostic pitfalls. Potential therapeutic options and an algorithm for the classification of the syndrome are proposed.

Entities:  

Mesh:

Year:  2004        PMID: 15221082     DOI: 10.1007/s00108-004-1229-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  55 in total

1.  CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART.

Authors:  D Scott-Algara; J P Aboulker; C Durier; E Badell; F Marcellin; M Prud'homme; C Jouanne; V Meiffredy; F Brun-Vezinet; G Pialoux; F Raffi
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

2.  CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.

Authors:  Christoph G Lange; Hernan Valdez; Kathy Medvik; Robert Asaad; Michael M Lederman
Journal:  Clin Immunol       Date:  2002-02       Impact factor: 3.969

3.  Reiter's syndrome as a manifestation of an immune reconstitution syndrome in an HIV-infected patient: successful treatment with doxycycline.

Authors:  Susanne Neumann; Florian Kreth; Stefan Schubert; Joachim Mossner; Karel Caca
Journal:  Clin Infect Dis       Date:  2003-06-15       Impact factor: 9.079

4.  Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.

Authors:  Shelley F Stone; Silvia Lee; Niamh M Keane; Patricia Price; Martyn A French
Journal:  J Infect Dis       Date:  2002-10-23       Impact factor: 5.226

5.  Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy.

Authors:  J M Naccache; M Antoine; M Wislez; J Fleury-Feith; E Oksenhendler; C Mayaud; J Cadranel
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

6.  Parvovirus B19 encephalitis presenting as immune restoration disease after highly active antiretroviral therapy for human immunodeficiency virus infection.

Authors:  Richard C Nolan; Glenys Chidlow; Martyn A French
Journal:  Clin Infect Dis       Date:  2003-04-14       Impact factor: 9.079

7.  Opportunistic infections occurring during highly active antiretroviral treatment.

Authors:  C Michelet; C Arvieux; C François; J M Besnier; J P Rogez; J P Breux; F Souala; C Allavena; F Raffi; M Garre; F Cartier
Journal:  AIDS       Date:  1998-10-01       Impact factor: 4.177

8.  Cytokines in leprosy, II. Effect of treatment on serum cytokines in leprosy.

Authors:  A D Moubasher; N A Kamel; H Zedan; D D Raheem
Journal:  Int J Dermatol       Date:  1998-10       Impact factor: 2.736

9.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

10.  Acute clinical hepatitis by immune restoration in a human immunodeficiency virus/hepatitis B virus co-infected patient receiving antiretroviral therapy.

Authors:  Isabelle Rouanet; Hélène Peyrière; Jean-Marc Mauboussin; Nicolas Terrail; Denis Vincent
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-01       Impact factor: 2.566

View more
  2 in total

1.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

2.  World Health Organization's stage 4 conditions among adults accessing outpatient HIV care: a retrospective cohort study in Kisumu, Kenya.

Authors:  Patrick O Owiti; Jeremy Penner; Arbogast Oyanga; Megan Huchko; Frankline M Onchiri; Craig Cohen; Elizabeth A Bukusi
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.